QuidelOrtho pre-announces Q1 revenue $840-850M; non-respiratory grows 5-7%

QuidelOrtho Corp

2023-Q1 EPS reported $0.73 revenue$846,100,000

Total preliminary Q1 revenue $840-850M; respiratory $262-267M including COVID-19 $212-217M.
Non-respiratory revenue $578-583M, up ~5% supplemental combined basis (~7% constant currency).
Labs business unit drove growth including ~$21M settlement from a collaboration agreement.
CEO Douglas Bryant says Q1 ahead of expectations; confident in sustainable high-single-digit growth.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

QuidelOrtho Corp reported first quarter ended April 2, 2023 results: revenue $840 million to $850 million.

Period: first quarter ended April 2, 2023
Revenue: $840 million to $850 million
Result: preliminary results

Exact text from the filing

today announced preliminary revenue results for the first quarter ended April 2, 2023. The Company expects total revenues in the first quarter of 2023 to be in the range of $840 million to $850 million. Respiratory product revenue is expected to be in the range of $262 million to $267 million, including COVID-19 product revenue of $212 million to $217 million.

View on SEC.gov

Browse all earnings releases →

QuidelOrtho Corp filing history →

Source: SEC EDGAR

accession 0001906324-23-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.